Abstract
Background:
There have been great concerns about pediatric thyroid cancers after the accident at the Fukushima Daiichi Nuclear Power Plant in 2011.
Case presentation:
We report a case of a 7-year-old Japanese girl with sporadic papillary thyroid carcinoma (PTC) harboring an ETV6/NTRK3 rearrangement. The patient presented with tumors in both lobes and underwent thyroidectomy followed by radioactive iodine (RAI) ablation. Histopathology showed a classic type of PTC with cervical lymph node metastasis.
Conclusions:
Genetic evaluation showed ETV6/NTRK3 fusion but no BRAF mutations or RET/PTC rearrangements. RET/PTC rearrangement and BRAF mutations often contribute to the pathogenesis of PTC; however, rearrangements of NTRK genes are relatively rare in pediatric PTC. Although NTRK rearrangement has been shown to often present unique pathological types and infiltrative architectures in the western population, such findings were not observed in this patient. Thus, the present case of classic PTC with ETV6/NTRK3 rearrangement highlights the disparate collection of clinic-pathological features compared to the trend in the western population. We therefore emphasize the need to further accumulate clinical as well as genetic data in pediatric PTCs.
Acknowledgments
We gratefully acknowledge the assistance of Dr. Sumito Dateki in preoperative diagnosis and hospitalization management. This work was supported in part through the Atomic Bomb Disease Institute, Nagasaki University, and by a Grant-in-Aid for Scientific Research from the Japanese Ministry of Education, Science, Sports, and Culture (No. 16K08714).
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. Cordioli MI, Moraes L, Bastos AU, Besson P, Alves MT, et al. Fusion oncogenes are the main genetic events found in sporadic papillary thyroid carcinomas from children. Thyroid 2017;27:182–8.10.1089/thy.2016.0387Search in Google Scholar
2. Prasad ML, Vyas M, Horne MJ, Virk RK, Morotti R, et al. NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States. Cancer 2016;122:1097–107.10.1002/cncr.29887Search in Google Scholar
3. Niedziela M. Pathogenesis, diagnosis and management of thyroid nodules in children. Endocr Relat Cancer 2006;13:427–53.10.1677/erc.1.00882Search in Google Scholar
4. Ricarte-Filho JC, Li S, Garcia-Rendueles ME, Montero-Conde C, Voza F, et al. Identification of kinase fusion oncogenes in post-Chernobyl radiation-induced thyroid cancers. J Clin Invest 2013;123:4935–44.10.1172/JCI69766Search in Google Scholar
5. Mitsutake N, Fukushima T, Matsuse M, Rogounovitch T, Saenko V, et al. BRAF(V600E) mutation is highly prevalent in thyroid carcinomas in the young population in Fukushima: a different oncogenic profile from Chernobyl. Sci Rep 2015;5:16976.10.1038/srep16976Search in Google Scholar
6. Fridman MV, Savva NN, Krasko OV, Zborovskaya AA, Mankovskaya SV, et al. Clinical and pathologic features of “sporadic” papillary thyroid carcinoma registered in the years 2005 to 2008 in children and adolescents of Belarus. Thyroid 2012;22:1016–24.10.1089/thy.2011.0005Search in Google Scholar
7. Sugino K, Nagahama M, Kitagawa W, Shibuya H, Ohkuwa K, et al. Papillary thyroid carcinoma in children and adolescents: long-term follow-up and clinical characteristics. World J Surg 2015;39:2259–65.10.1007/s00268-015-3042-4Search in Google Scholar
8. Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell 2014; 159:676–90.10.1016/j.cell.2014.09.050Search in Google Scholar
9. Soares P, Trovisco V, Rocha AS, Lima J, Castro P, et al. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 2003; 22:4578–80.10.1038/sj.onc.1206706Search in Google Scholar
10. Rossi M, Buratto M, Tagliati F, Rossi R, Lupo S, et al. Relevance of BRAF(V600E) mutation testing versus RAS point mutations and RET/PTC rearrangements evaluation in the diagnosis of thyroid cancer. Thyroid 2015;25:221–8.10.1089/thy.2014.0338Search in Google Scholar
11. Niemeier LA, Kuffner Akatsu H, Song C, Carty SE, Hodak SP, et al. A combined molecular-pathologic score improves risk stratification of thyroid papillary microcarcinoma. Cancer 2012;118:2069–77.10.1002/cncr.26425Search in Google Scholar
12. Xing M, Alzahrani AS, Carson KA, Shong YK, Kim TY, et al. Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. J Clin Oncol 2015;33:42–50.10.1200/JCO.2014.56.8253Search in Google Scholar
13. Penko K, Livezey J, Fenton C, Patel A, Nicholson D, et al. BRAF mutations are uncommon in papillary thyroid cancer of young patients. Thyroid 2005;15:320–5.10.1089/thy.2005.15.320Search in Google Scholar
14. Rosenbaum E, Hosler G, Zahurak M, Cohen Y, Sidransky D, et al. Mutational activation of BRAF is not a major event in sporadic childhood papillary thyroid carcinoma. Mod Pathol 2005;18:898–902.10.1038/modpathol.3800252Search in Google Scholar
15. Leeman-Neill RJ, Kelly LM, Liu P, Brenner AV, Little MP, et al. ETV6-NTRK3 is a common chromosomal rearrangement in radiation-associated thyroid cancer. Cancer 2014;120:799–807.10.1002/cncr.28484Search in Google Scholar
16. Knezevich SR, McFadden DE, Tao W, Lim JF, Sorensen PH. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nature Genet 1998;18:184–7.10.1038/ng0298-184Search in Google Scholar
17. Rubin BP, Chen CJ, Morgan TW, Xiao S, Grier HE, et al. Congenital mesoblastic nephroma t(12;15) is associated with ETV6-NTRK3 gene fusion: cytogenetic and molecular relationship to congenital (infantile) fibrosarcoma. Am J Pathol 1998;153:1451–8.10.1016/S0002-9440(10)65732-XSearch in Google Scholar
18. Tognon C, Knezevich SR, Huntsman D, Roskelley CD, Melnyk N, et al. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell 2002;2:367–76.10.1016/S1535-6108(02)00180-0Search in Google Scholar
19. Eguchi M, Eguchi-Ishimae M, Tojo A, Morishita K, Suzuki K, et al. Fusion of ETV6 to neurotrophin-3 receptor TRKC in acute myeloid leukemia with t(12;15)(p13;q25). Blood 1999;93:1355–63.10.1182/blood.V93.4.1355Search in Google Scholar
20. Carroll M, Tomasson MH, Barker GF, Golub TR, Gilliland DG. The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways. Proc Natl Acad Sci USA 1996;93:14845–50.10.1073/pnas.93.25.14845Search in Google Scholar
21. Golub TR, Goga A, Barker GF, Afar DE, McLaughlin J, et al. Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia. Mol Cell Biol 1996;16:4107–16.10.1128/MCB.16.8.4107Search in Google Scholar
©2018 Walter de Gruyter GmbH, Berlin/Boston